These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 18471791)

  • 21. The role of the stromal microenvironment in prostate cancer.
    Condon MS
    Semin Cancer Biol; 2005 Apr; 15(2):132-7. PubMed ID: 15652458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New results from the use of bisphosphonates in cancer patients.
    Coleman R; Gnant M
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):213-8. PubMed ID: 19561507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Penta-O-galloyl-beta-D-glucose suppresses prostate cancer bone metastasis by transcriptionally repressing EGF-induced MMP-9 expression.
    Kuo PT; Lin TP; Liu LC; Huang CH; Lin JK; Kao JY; Way TD
    J Agric Food Chem; 2009 Apr; 57(8):3331-9. PubMed ID: 19320436
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of hormone refractory prostate cancer.
    Lin AM; Small EJ
    Curr Opin Support Palliat Care; 2007 Oct; 1(3):187-91. PubMed ID: 18685361
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer.
    Rozková D; Tiserová H; Fucíková J; Last'ovicka J; Podrazil M; Ulcová H; Budínský V; Prausová J; Linke Z; Minárik I; Sedivá A; Spísek R; Bartůnková J
    Clin Immunol; 2009 Apr; 131(1):1-10. PubMed ID: 19201656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metastatic adenocarcinoma of prostate in a healing sternotomy site.
    Adams G; Mitchell A; Ravichandran R; Beer TM; Garzotto M
    Urology; 2006 Jul; 68(1):204.e13-5. PubMed ID: 16808964
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bone directed therapies for prostate cancer.
    Bradley DA; Hussain M; Dipaola RS; Kantoff P
    J Urol; 2007 Sep; 178(3 Pt 2):S42-8. PubMed ID: 17644119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate cancer, serum parathyroid hormone, and the progression of skeletal metastases.
    Schwartz GG
    Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):478-83. PubMed ID: 18349265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
    Amato RJ; Hernandez-McClain J; Henary H
    Am J Clin Oncol; 2008 Dec; 31(6):532-8. PubMed ID: 19060583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism of bone metastasis: the role of osteoprotegerin and of the host-tissue microenvironment-related survival factors.
    Fili S; Karalaki M; Schaller B
    Cancer Lett; 2009 Sep; 283(1):10-9. PubMed ID: 19201081
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Growth hormone inhibitors in prostate cancer: a systematic analysis.
    Schmid HP; Gregorin J; Altwein JE
    Urol Int; 2008; 81(1):17-22. PubMed ID: 18645266
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer.
    Petrioli R; Fiaschi AI; Francini E; Pascucci A; Francini G
    Cancer Treat Rev; 2008 Dec; 34(8):710-8. PubMed ID: 18620815
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Slow zoledronic acid releasing testis prostheses in the treatment of prostate cancer patients with bone metastases.
    Serefoglu EC; Balbay MD
    Med Hypotheses; 2009 Sep; 73(3):387-8. PubMed ID: 19403241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
    James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
    Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate-specific antigen enhances bioavailability of insulin-like growth factor by degrading insulin-like growth factor binding protein 5.
    Maeda H; Yonou H; Yano K; Ishii G; Saito S; Ochiai A
    Biochem Biophys Res Commun; 2009 Apr; 381(3):311-6. PubMed ID: 19250630
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells.
    Fernández-Martínez AB; Bajo AM; Sánchez-Chapado M; Prieto JC; Carmena MJ
    Prostate; 2009 May; 69(7):774-86. PubMed ID: 19189304
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Osteotropic cancers: from primary tumor to bone.
    Buijs JT; van der Pluijm G
    Cancer Lett; 2009 Jan; 273(2):177-93. PubMed ID: 18632203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Examining the metastatic niche: targeting the microenvironment.
    Guise T
    Semin Oncol; 2010 Oct; 37 Suppl 2():S2-14. PubMed ID: 21111245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Can conception of prostate cancer stem cells influence treatment dedicated to patients with disseminated disease?
    Drewa T; Styczynski J
    Med Hypotheses; 2008 Nov; 71(5):694-9. PubMed ID: 18706770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone morphogenetic protein-9 induces apoptosis in prostate cancer cells, the role of prostate apoptosis response-4.
    Ye L; Kynaston H; Jiang WG
    Mol Cancer Res; 2008 Oct; 6(10):1594-606. PubMed ID: 18922975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.